Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02087176 · ClinicalTrials.gov registry record · Phase 2
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02087176 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 48 participants.
The verdict
NCT02087176, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell Lung Cancer Patients
Interventions
- DRUG AZD1775
- DRUG AZD1775 Placebo
- DRUG Antimitotic Agent
- DRUG pegfiligrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02087176
The ClinicalTrials.gov registry entry for NCT02087176 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AZD1775 is the first listed.
NCT02087176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02087176 about?
NCT02087176 is a clinical study titled "A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer". A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell Lung Cancer Patients
What is the current status of trial NCT02087176?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2014-03. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02087176?
The interventions under investigation include: AZD1775 (DRUG), AZD1775 Placebo (DRUG), Antimitotic Agent (DRUG), pegfiligrastim (DRUG).
Who is sponsoring clinical trial NCT02087176?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.